LS 301 IT
Alternative Names: LS-301-ITLatest Information Update: 12 Dec 2024
At a glance
- Originator Integro Theranostics
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Breast cancer
- Phase I Lung cancer
- Preclinical Gynaecological cancer
Most Recent Events
- 11 Nov 2024 Phase-I clinical trials in Lung cancer (Diagnosis) in USA (IV) (NCT06713564)
- 24 Jul 2023 Integro Theranostics plans a phase Ib/II trial for Breast cancer (Diagnosis, In adults, In the elderly) in USA (IV, Injection), in July 2023 (Integro Theranostics pipeline, July 2023) (NCT05900986)
- 24 Jul 2023 Preclinical trials in Gynaecological cancer (Diagnosis) in USA (IV), prior to July 2023 (Integro Theranostics pipeline, July 2023)